You are here
FDA Notifies Health Care Professionals About Prescribing Errors Involving Zyprexa and Zyrtec
February 9, 2005
Eli Lilly and FDA notified healthcare professionals reports of medication dispensing or prescribing errors between the atypical antipsychotic ZyPREXA (olanzapine), indicated for the short-term and maintenance treatment of schizophrenia and for the short-term treatment of acute mixed or manic episodes associated with Bipolar I Disorder, and the antihistamine ZYRTEC (cetirizine HCI) marketed by Pfizer, indicated for the treatment of allergic rhinitis or chronic urticaria. These reports include instances where Zyprexa was incorrectly dispensed for Zyrtec and vice versa, leading to unnecessary adverse events or potential relapse in patients suffering from schizophrenia or bipolar disorder.
To review the letter from Eli Lilly, click here.
Source: The Food and Drug Administration
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs